# Epacadostat, Cladribine and Cytarabine (ECC) in AML

> **NCT03491579** · PHASE1 · WITHDRAWN · sponsor: **Insel Gruppe AG, University Hospital Bern**

## Conditions studied

- AML
- Relapse

## Interventions

- **DRUG:** Epacadostat
- **DRUG:** Cladribine
- **DRUG:** Cytarabine

## Key facts

- **NCT ID:** NCT03491579
- **Lead sponsor:** Insel Gruppe AG, University Hospital Bern
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2018-12
- **Primary completion:** 2019-09
- **Final completion:** 2019-10
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** IMP will not be further developed
- **Last updated:** 2018-09-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03491579

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03491579, "Epacadostat, Cladribine and Cytarabine (ECC) in AML". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03491579. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*